Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Issue 12 (20th April 2023)

• Record Type: Journal Article
• Authors: Ludford, Kaysia; Ho, Won Jin; Thomas, Jane V.; Raghav, Kanwal P.S.; Murphy, Mariela Blum; Fleming, Nicole D.; Lee, Michael S.; Smaglo, Brandon G.; You, Y. Nancy; Tillman, Matthew M.; Kamiya-Matsuoka, Carlos; Thirumurthi, Selvi; Messick, Craig; Johnson, Benny; Vilar, Eduardo; Dasari, Arvind; Shin, Sarah; Hernandez, Alexei; Yuan, Xuan; Yang, Hongqui; Foo, Wai Chin; Qiao, Wei; Maru, Dipen; Kopetz, Scott; Overman, Michael J.
• Is Part Of: Journal of clinical oncology. Volume 41:Issue 12(2023)
• Page Start: 2181
• Page End: 2190
• Publication Date: 2023-04-20
• Subjects: Oncology -- Periodicals; Cancer -- Periodicals; Oncology; Medical Oncology; Cancérologie -- Périodiques; Cancer -- Périodiques; Cancérologie; Cancer; Oncology; Oncologia; Càncer; Periodicals; 616.994
• DOI: 10.1200/JCO.22.01351
• Languages: English
• ISSNs: 0732-183X

Abstract

Abstract : PURPOSE: Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space. METHODS: This is a phase II open-label, single-center trial of localized unresectable or high-risk resectable MSI-H/dMMR tumors. Treatment is pembrolizumab 200 mg once every 3 weeks for 6 months followed by surgical resection with an option to continue therapy for 1 year followed by observation. To continue on study, patients are required to have radiographic or clinical benefit. The coprimary end points are safety and pathologic complete response. Key secondary end points are response rate and organ-sparing at one year for patients who declined surgery. Exploratory analyses include interrogation of the tumor immune microenvironment using imaging mass cytometry. RESULTS: A total of 35 patients were enrolled, including 27 patients with colorectal cancer and eight patients with noncolorectal cancer. Among 33 evaluable patients, best overall response rate was 82%. Among 17 (49%) patients who underwent surgery, the pathologic complete response rate was 65%. Ten patients elected to receive one year of pembrolizumab followed by surveillance without surgical resection (median follow-up of 23 weeks [range, 0-54 weeks]). An additional eight did not undergo surgical resection and received less than 1 year of pembrolizumab. During the study course of the trial and subsequent follow-up, progression events were seen in six patients (four of whom underwent salvage surgery). There were no new safety signals. Spatial immune profiling with imaging mass cytometry noted a significantly closer proximity between granulocytic cells and cytotoxic T cells in patients with progressive events compared with those without progression. CONCLUSION: Neoadjuvant pembrolizumab in dMMR/MSI-H cancers is safe and resulted in high rates of pathologic, radiographic, and endoscopic response, which has implications for organ-sparing strategies.